SCHEMBL18878385

SCHEMBL18878385

Cc1c(CC(C)C)ccc(C(=O)C(C)C)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.38
GABRB2 P47870 2/20 0.38
ELANE P08246 1/20 0.35
CTSG P08311 1/20 0.35
ALDH1A1 P00352 3/20 0.34
HPGD P15428 1/20 0.34
PTGS1 P23219 3/20 0.33
PTGS2 P35354 3/20 0.33
LMNA P02545 2/20 0.33
CYP2C9 P11712 2/20 0.33
AKR1C3 P42330 2/20 0.33
CXCR1 P25024 2/20 0.33
CXCR2 P25025 2/20 0.33
POLB P06746 2/20 0.33
ALB P02768 1/20 0.33
ESR1 P03372 1/20 0.33
ALOX5 P09917 1/20 0.33
RARB P10826 1/20 0.33
ADRB3 P13945 1/20 0.33
NFKB1 P19838 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18878386 0.73 POLB (0.36) ALDH1A1POLBL3MBTL1
SCHEMBL18878383 0.71 GABRA1 (0.47) GABRA1GABRB2PTGS1PTGS2LMNA
SCHEMBL29217394 0.70 KMT2A (0.41) GABRA1GABRB2ALDH1A1CYP2C9TSHR
SCHEMBL18878382 0.70 NPSR1 (0.37) GABRA1GABRB2ALDH1A1POLBL3MBTL1
SCHEMBL23387408 0.70 GABRA1 (0.61) GABRA1GABRB2ELANECTSGALDH1A1
SCHEMBL18878380 0.69 KDM4E (0.50) GABRA1GABRB2HPGDLMNASMN1; SMN2
SCHEMBL18878377 0.69 FFAR1 (0.40) GABRA1GABRB2ALDH1A1HPGDLMNA
SCHEMBL4627364 0.68 ALDH1A1 (0.47) ALDH1A1HPGDLMNACYP2C9POLB
SCHEMBL17058840 0.68 ALDH1A1 (0.31) ALDH1A1
SCHEMBL9186673 0.67 ESR1 (0.46) ALDH1A1HPGDPTGS1PTGS2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951074-B2 Dihydropteridinone derivatives and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-04-24 US disclosed
US-20170145013-A1 DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170145013-A1 DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF BRDT, BRD4, BRD3 GABRA1 2843/4885GABRB2 1247/4885ELANE 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.